First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer (AICE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Shanghai Gynecologic Oncology Group
Fudan University
Shanghai Jiao Tong University School of Medicine
Shanghai Zhongshan Hospital
Information provided by (Responsible Party):
Shanghai Gynecologic Oncology Group Identifier:
First received: August 8, 2012
Last updated: October 30, 2015
Last verified: May 2015
The purpose of this study is to evaluate the role of an additional intraperitoneal chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.

Condition Intervention Phase
Bulky Stage IIIC and IV Epithelial Ovarian Cancer,
Fallopian Tube Cancer,
Primary Peritoneal Carcinoma
Drug: PEip (weekly) and TCiv
Drug: TCiv
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)

Resource links provided by NLM:

Further study details as provided by Shanghai Gynecologic Oncology Group:

Primary Outcome Measures:
  • 12-month disease non-progression rate [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: up to 120 months ] [ Designated as safety issue: No ]
  • Completion rate of intraperitoneal chemotherapy. [ Time Frame: up to 6 months ] [ Designated as safety issue: Yes ]
  • Quality of life assessments [ Time Frame: baseline; 4th week of intraperitoneal,chemotherapy, 6th cycle of intravenous chemotherpy, 3, 6, and 12 months after first-line chemotherapy. ] [ Designated as safety issue: No ]
  • Overall Survival [ Time Frame: up to 120 months ] [ Designated as safety issue: No ]
  • adverse effects [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 5 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 200
Study Start Date: April 2009
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Regimen B, PEip and TCiv therapy
Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin
Drug: PEip (weekly) and TCiv
IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
Other Names:
  • platinum
  • VP 16
  • taxane
Active Comparator: Regimen A: Standard TCiv therapy
IV paclitaxel plus carboplatin or docetaxel plus carboplatin
Drug: TCiv
IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
Other Names:
  • taxane
  • platinum

Detailed Description:
This exploratory trial is to compare the efficacy of sequential chemotherapy, intraperitoneal chemotherapy followed by intravenous chemotherapy, versus intravenous chemotherapy alone in the first-line therapy for ovarian cancer.

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥18 years to ≤ 75 years.
  • Epithelial ovarian cancer with pathology confirmed stage IIIc or IV, expect for lymph node metastasis alone
  • Optimal cytoreductive surgery, including hysterectomy, bilateral salpinges-oophorectomy, omentectomy, and resection of all metastatic lesions, with a residual disease no more than 1cm
  • Available to receive intraperitoneal chemotherapy 5-10 days postoperative, or no more than postoperative 14 days for those with bowel resection.
  • ECOG performance 0-2.
  • No more than 3 cycles of chemotherapy prior to surgery.
  • Laboratory testing within 7 days of registration: hematopoietic: absolute neutrophil count greater than 1,500/mm3; Platelet count greater than 100,000/mm3. Hepatic: bilirubin less than 1.25 times upper limit of normal (ULN); Bilirubin < 2.0, SGPT less than 2 times ULN. Renal: creatinine less than 1.6 mg/dL, OR creatinine clearance greater than 40 mL/min.
  • Comply with intraperitoneal chemotherapy and follow-up.
  • Written informed consent.

Exclusion Criteria:

  • Low-malignant potential ovarian tumor.
  • Laboratory testing insufficiency. Hemoglobin < 10 g/dL. Renal insufficiency with serum creatinine > 1.6.
  • Bone marrow dysfunction: absolute neutrophil count less than 1,500/mm3; Platelet count less than 80,000/mm3.
  • Active infection.
  • Clinically significant gastrointestinal abnormalities.
  • Active coronary artery disease, cerebrovascular disease, restrictive or obstructive pulmonary disease, or congestive heart failure.
  • Other condition that could interfere with provision of informed consent, compliance to study procedures, or follow-up.
  • Prior invasive malignancies within the last 5 years showing activity of disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01669226

Contact: Jie Tang, MD,PhD +862164175590
Contact: Yuting Luan, RN +862164175590

China, Jiangsu
Zhongda Hospital Southeast University Recruiting
Nanjing, Jiangsu, China, 210009
Contact: Yang Shen, MD    86 25 83272111   
Suzhou Municipal Hospital Recruiting
Suzhou, Jiangsu, China
Contact: Mi Zhang, MD    +8613584887057   
Wuxi Cancer Hospital Recruiting
Wuxi, Jiangsu, China
Contact: Shan Su, MD    +8613861768827   
China, Shanghai
Shanghai Zhongshan Hospital Recruiting
Shanghai, Shanghai, China, 200030
Contact: Rong Jiang, MD    86 21 64041990 ext 2905   
Ren Ji Hospital Affiliated to Shanghai JiaoTong University School of Medicine Not yet recruiting
Shanghai, Shanghai, China
Contact: Lihua Qiu, MD,PhD    +862158752345   
Shanghai Frist Maternity and Infant Hospital Affiliated to Tongji University Not yet recruiting
Shanghai, Shanghai, China
Contact: Xipeng Wang, MD,PhD   
Fudan University Cancer Hospital Recruiting
Shanghai, China, 200032
Contact: Yuting Luan, RN    +862164175590   
Principal Investigator: Rongyu Zang, MD,PhD         
Sponsors and Collaborators
Shanghai Gynecologic Oncology Group
Fudan University
Shanghai Jiao Tong University School of Medicine
Shanghai Zhongshan Hospital
Principal Investigator: Rongyu Zang, MD,PhD Shanghai Gynecologic Oncology Group
  More Information

Additional Information:
Responsible Party: Shanghai Gynecologic Oncology Group Identifier: NCT01669226     History of Changes
Other Study ID Numbers: V01-2009-03 
Study First Received: August 8, 2012
Last Updated: October 30, 2015
Health Authority: China: Ethics Committee

Keywords provided by Shanghai Gynecologic Oncology Group:
Ovarian Cancer
intraperitoneal chemotherapy

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Etoposide phosphate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on May 01, 2016